Baxter’s Amia Automated Home Dialysis System Receives FDA Clearance
Executive Summary
Baxter received FDA 510(k) clearance in October for Amia, a home-based automated peritoneal dialysis system that features voice guidance, touchscreen control and two-way connectivity. With more than 600,000 people in the US living with end-stage renal disease, and 40,000 of these on peritoneal dialysis, the company is working to enhance renal care with patient-centric technologies that provide more individualized and efficient home-based therapy.
You may also be interested in...
US Filing Eyed After Qurient's Novel TB Candidate Proves Mettle
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.
DHS Guidance Smooths Potential Wrinkles In US Supplement Industry Being ‘Essential’ Nationwide
VMS businesses are deemed essential in Department of Homeland Security guidance that provides as basis for orders by most states and localities across the US. During an AHPA webinar, attorney Trent Norris says the federal government prefers leaving business exemptions to shut-down decisions to the states.
J&J Ramps Up Manufacturing Capacity To Produce 1 Billion Doses Of Candidate COVID-19 Vaccine
Company expects clinical trials to begin by September and says first batches could be available for emergency use authorization in early 2021; J&J pledges vaccine will be available to public on not-for-profit basis.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: